Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.

about

Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.

Item

http://www.wikidata.org/entity/Q47121796

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effect of antitumor treatments ...... randomized controlled trials.

@en

Effect of antitumor treatments ...... randomized controlled trials.

@nl

type

Item

label

Effect of antitumor treatments ...... randomized controlled trials.

@en

Effect of antitumor treatments ...... randomized controlled trials.

@nl

prefLabel

Effect of antitumor treatments ...... randomized controlled trials.

@en

Effect of antitumor treatments ...... randomized controlled trials.

@nl

P1476

Effect of antitumor treatments ...... randomized controlled trials.

@en

P2093

Jinsheng Zeng

http://www.w3.org/2001/XMLSchema#string

Peng Du

http://www.w3.org/2001/XMLSchema#string

Qiuhong Tian

http://www.w3.org/2001/XMLSchema#string

Sen Li

http://www.w3.org/2001/XMLSchema#string

Yong Yang

http://www.w3.org/2001/XMLSchema#string

Zhenzhu Bai

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Triple-Negative Breast Cancer

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.

P304

e8389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1097/MD.0000000000008389

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29137021

http://www.w3.org/2001/XMLSchema#string

P932

5690714

http://www.w3.org/2001/XMLSchema#string